Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2007-10-01 15:58 |
WILEX AG: Supervisory Board appoints Thomas Borcholte as Chief Business Officer…
|
English | 3.8 KB | ||
| 2007-10-01 15:44 |
WILEX AG: Supervisory Board appoints Dr. Thomas Borcholte as Chief Business Off…
|
English | 3.5 KB | ||
| 2007-09-24 09:56 |
WILEX AG: Phase Ib trial with WX-671 in patients with head & neck cancer succes…
|
English | 4.5 KB | ||
| 2007-07-12 08:37 |
WILEX HY1 2007: projects in line with expectations improved financial outlook
|
English | 8.9 KB | ||
| 2007-07-12 08:29 |
WILEX AG:
|
English | 3.3 KB | ||
| 2007-07-12 00:00 |
Q2 Report 2007/2008
|
German | 1.1 MB | ||
| 2007-07-03 10:22 |
WILEX AG: SAVE THE DATE: First international symposium on functional and clinic…
|
English | 4.8 KB | ||
| 2007-07-02 14:36 |
DGAP-DD: WILEX AG english
|
English | 1.5 KB | ||
| 2007-06-29 09:14 |
WILEX to follow FDA advice and apply for a special protocol assessment (SPA) fo…
|
English | 6.0 KB | ||
| 2007-06-26 11:47 |
WILEX AG: Patient recruitment started in clinical Phase II trial with WX-671 in…
|
English | 5.1 KB | ||
| 2007-06-15 09:01 |
DGAP-DD: WILEX AG english
|
English | 1.5 KB | ||
| 2007-06-13 10:02 |
WILEX AG: Annual General Meeting appoints new Supervisory Board members
|
English | 4.1 KB | ||
| 2007-04-13 08:01 |
WILEX publishes Q1 2007 figures results in line with expectations
|
English | 5.3 KB | ||
| 2007-04-13 00:00 |
Q1 Report 2006/2007
|
German | 120.6 KB | ||
| 2007-04-03 10:22 |
WILEX gives positive update of current pivotal Phase III trial of RENCAREX
|
English | 5.2 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
